(Q38297729)

1 September 2017

1 reference

title

Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity (English)

1 reference

1 September 2017

0 references

0 references

1 reference

1

Margaret A Knowles

0 references

author name string

Carolyn D Hurst

series ordinal

2

1 reference

PubMed ID

25533674

1 September 2017

language of work or name

English

0 references

publication date

1 January 2015

1 reference

PubMed ID

25533674

full work available at URL

1 September 2017

http://eprints.whiterose.ac.uk/86541/

content deliverer

White Rose Research Online

object has role

postprint

0 references

published in

Nature Reviews Cancer

1 reference

1 September 2017

15

1 reference

1 September 2017

1

1 reference

1 September 2017

25-41

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc3817

1 September 2017

0 references

cites work

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms?

21 January 2018

1 reference

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

21 January 2018

1 reference

Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer

21 January 2018

1 reference

DNA double strand break repair in human bladder cancer is error prone and involves microhomology-associated end-joining

21 January 2018

1 reference

Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.

21 January 2018

1 reference

Frequent truncating mutations of STAG2 in bladder cancer

21 January 2018

1 reference

Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes

21 January 2018

1 reference

Mutational inactivation of STAG2 causes aneuploidy in human cancer

21 January 2018

1 reference

CTCF and cohesin cooperate to organize the 3D structure of the mammalian genome

21 January 2018

1 reference

Distinct functions of human cohesin-SA1 and cohesin-SA2 in double-strand break repair

21 January 2018

1 reference

Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation

21 January 2018

1 reference

p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer.

21 January 2018

1 reference

Alteration of the PATCHED locus in superficial bladder cancer

21 January 2018

1 reference

PTCH gene mutations in invasive transitional cell carcinoma of the bladder

21 January 2018

1 reference

Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33.

21 January 2018

1 reference

A sequence-ready 840-kb PAC contig spanning the candidate tumor suppressor locus DBC1 on human chromosome 9q32-q33.

21 January 2018

1 reference

Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.

21 January 2018

1 reference

A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.

21 January 2018

1 reference

The INK4a/ARF locus in murine tumorigenesis

21 January 2018

1 reference

CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.

21 January 2018

1 reference

Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status.

21 January 2018

1 reference

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer

21 January 2018

1 reference

A new tumor suppressor role for the Notch pathway in bladder cancer

21 January 2018

1 reference

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder

21 January 2018

1 reference

Comprehensive molecular characterization of urothelial bladder carcinoma

21 January 2018

1 reference

The bladder cancer genome; chromosomal changes as prognostic makers, opportunities, and obstacles

21 January 2018

1 reference

Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

21 January 2018

1 reference

Bladder cancer subtypes defined by genomic alterations

21 January 2018

1 reference

Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma

21 January 2018

1 reference

Copy number alterations in urothelial carcinomas: their clinicopathological significance and correlation with DNA methylation alterations

21 January 2018

1 reference

Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis

21 January 2018

1 reference

Detailed Analysis of Focal Chromosome Arm 1q and 6p Amplifications in Urothelial Carcinoma Reveals Complex Genomic Events on 1q, and SOX4 as a Possible Auxiliary Target on 6p.

21 January 2018

1 reference

Oncogenic FGFR3 gene fusions in bladder cancer

21 January 2018

1 reference

Mutational context and diverse clonal development in early and late bladder cancer.

21 January 2018

1 reference

Mutational heterogeneity in cancer and the search for new cancer-associated genes

21 January 2018

1 reference

An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers

21 January 2018

1 reference

Evidence for APOBEC3B mutagenesis in multiple human cancers

21 January 2018

1 reference

Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.

21 January 2018

1 reference

Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.

21 January 2018

1 reference

The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour.

21 January 2018

1 reference

Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur

21 January 2018

1 reference

Prediction of Progression of Non–Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study

21 January 2018

1 reference

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

21 January 2018

1 reference

The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas.

21 January 2018

1 reference

FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer

21 January 2018

1 reference

Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner

21 January 2018

1 reference

A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer

21 January 2018

1 reference

Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines

21 January 2018

1 reference

Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family

21 January 2018

1 reference

Distinct microRNA alterations characterize high- and low-grade bladder cancer

21 January 2018

1 reference

Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer

21 January 2018

1 reference

Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer

21 January 2018

1 reference

FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCγ/COX-2-mediated mechanisms

21 January 2018

1 reference

Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting

21 January 2018

1 reference

Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer

21 January 2018

1 reference

Expression of NRG1 and its receptors in human bladder cancer

21 January 2018

1 reference

Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.

21 January 2018

1 reference

Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder

21 January 2018

1 reference

Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation

21 January 2018

1 reference

Profiling bladder cancer using targeted antibody arrays

21 January 2018

1 reference

PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

21 January 2018

1 reference

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

21 January 2018

1 reference

Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

21 January 2018

1 reference

PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs

21 January 2018

1 reference

Somatic mutation of PTEN in bladder carcinoma

21 January 2018

1 reference

Inactivation of p53 and Pten promotes invasive bladder cancer

21 January 2018

1 reference

PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity

21 January 2018

1 reference

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

21 January 2018

1 reference

Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations.

21 January 2018

1 reference

Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines

21 January 2018

1 reference

Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication

21 January 2018

1 reference

Aberrant expression of beta-catenin and mutation of exon 3 of the beta-catenin gene in renal and urothelial carcinomas.

21 January 2018

1 reference

Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors

21 January 2018

1 reference

Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway

21 January 2018

1 reference

β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation.

21 January 2018

1 reference

Constitutive β-catenin activation induces male-specific tumorigenesis in the bladder urothelium

21 January 2018

1 reference

Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis

21 January 2018

1 reference

Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder

21 January 2018

1 reference

Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma

21 January 2018

1 reference

Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors

21 January 2018

1 reference

Hedgehog signaling in normal urothelial cells and in urothelial carcinoma cell lines

21 January 2018

1 reference

Prognostic value of cell-cycle regulation biomarkers in bladder cancer.

21 January 2018

1 reference

Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification.

21 January 2018

1 reference

Epigenetic biomarkers in urothelial bladder cancer

21 January 2018

1 reference

Global epigenetic profiling in bladder cancer.

21 January 2018

1 reference

Hypermethylation in bladder cancer: biological pathways and translational applications

21 January 2018

1 reference

Epigenetics of kidney cancer and bladder cancer

21 January 2018

1 reference

Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers

21 January 2018

1 reference

Identification of methylated genes associated with aggressive bladder cancer

21 January 2018

1 reference

Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue

21 January 2018

1 reference

DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status

21 January 2018

1 reference

Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing

21 January 2018

1 reference

Integrated epigenome profiling of repressive histone modifications, DNA methylation and gene expression in normal and malignant urothelial cells

21 January 2018

1 reference

A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression

21 January 2018

1 reference

Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis.

21 January 2018

1 reference

Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments

21 January 2018

1 reference

A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine.

21 January 2018

1 reference

Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples

21 January 2018

1 reference

A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.

21 January 2018

1 reference

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome

21 January 2018

1 reference

Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine

21 January 2018

1 reference

The uroepithelium: not just a passive barrier

21 January 2018

1 reference

The human urothelium consists of multiple clonal units, each maintained by a stem cell

21 January 2018

1 reference

Normal and neoplastic urothelial stem cells: getting to the root of the problem

21 January 2018

1 reference

Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma

21 January 2018

1 reference

Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma.

21 January 2018

1 reference

Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells

21 January 2018

1 reference

Three differentiation states risk-stratify bladder cancer into distinct subtypes

21 January 2018

1 reference

Bladder cancers arise from distinct urothelial sub-populations.

21 January 2018

1 reference

Analysis of genetic alterations in normal bladder urothelium.

21 January 2018

1 reference

Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma

21 January 2018

1 reference

Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder.

21 January 2018

1 reference

Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma

21 January 2018

1 reference

Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development

21 January 2018

1 reference

Status of the p53, p16, RB1, and HER-2 genes and chromosomes 3, 7, 9, and 17 in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters

21 January 2018

1 reference

Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia

21 January 2018

1 reference

Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy

21 January 2018

1 reference

Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor.

21 January 2018

1 reference

Origin of multifocal carcinomas of the bladder and upper urinary tract: molecular analysis and clinical implications

21 January 2018

1 reference

Genetic analysis of multifocal superficial urothelial cancers by array-based comparative genomic hybridisation

21 January 2018

1 reference

Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis

21 January 2018

1 reference

Regulation of epithelial-mesenchymal and mesenchymal-epithelial transitions by microRNAs

21 January 2018

1 reference

Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer.

21 January 2018

1 reference

miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy

21 January 2018

1 reference

Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2.

21 January 2018

1 reference

A novel role of Id-1 in regulation of epithelial-to-mesenchymal transition in bladder cancer

21 January 2018

1 reference

Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression

21 January 2018

1 reference

TGF-β-induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12.

21 January 2018

1 reference

Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression

21 January 2018

1 reference

The p63 protein isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205.

21 January 2018

1 reference

p63 expression defines a lethal subset of muscle-invasive bladder cancers

21 January 2018

1 reference

Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology

21 January 2018

1 reference

The faces and friends of RhoGDI2.

21 January 2018

1 reference

Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function.

21 January 2018

1 reference

The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder.

21 January 2018

1 reference

RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration

21 January 2018

1 reference

RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment

21 January 2018

1 reference

ATF3 suppresses metastasis of bladder cancer by regulating gelsolin-mediated remodeling of the actin cytoskeleton.

21 January 2018

1 reference

The Ral GTPase pathway in metastatic bladder cancer: key mediator and therapeutic target

21 January 2018

1 reference

Downregulation of Ral GTPase-activating protein promotes tumor invasion and metastasis of bladder cancer

21 January 2018

1 reference

CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization

21 January 2018

1 reference

CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated

21 January 2018

1 reference

Bladder cancer outcome and subtype classification by gene expression

21 January 2018

1 reference

Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR.

21 January 2018

1 reference

Identifying distinct classes of bladder carcinoma using microarrays.

21 January 2018

1 reference

Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.

21 January 2018

1 reference

Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer

21 January 2018

1 reference

A molecular taxonomy for urothelial carcinoma.

21 January 2018

1 reference

Toward a molecular pathologic classification of urothelial carcinoma.

21 January 2018

1 reference

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy

21 January 2018

1 reference

Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer

21 January 2018

1 reference

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin

21 January 2018

1 reference

EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype

21 January 2018

1 reference

DNA methylation profiles delineate etiologic heterogeneity and clinically important subgroups of bladder cancer

21 January 2018

1 reference

Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.

21 January 2018

1 reference

Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers

21 January 2018

1 reference

Epigenetic Inactivation of SFRP Genes and TP53 Alteration Act Jointly as Markers of Invasive Bladder Cancer

21 January 2018

1 reference

Bladder cancer: Lack of progress in bladder cancer--what are the obstacles?

21 January 2018

1 reference

Rates of p16 (MTS1) mutations in primary tumors with 9p loss

31 March 2020

1 reference

Prognostic value of loss of heterozygosity at chromosome 9p in non-muscle-invasive bladder cancer

31 March 2020

1 reference

P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma

31 March 2020

1 reference

Loss of P16 Expression and Chromosome 9p21 LOH in Predicting Outcome of Patients Affected by Superficial Bladder Cancer

31 March 2020

1 reference

p16INK4A and p19ARF act in overlapping pathways in cellular immortalization

31 March 2020

1 reference

Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer

31 March 2020

1 reference

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

31 March 2020

1 reference

The FGFR3 mutation is related to favorable pT1 bladder cancer.

31 March 2020

1 reference

HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications

31 March 2020

1 reference

Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer

31 March 2020

1 reference

Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder

31 March 2020

1 reference

Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer

31 March 2020

1 reference

The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy

31 March 2020

1 reference

Combinations of Urinary Biomarkers for Surveillance of Patients with Incident Nonmuscle Invasive Bladder Cancer: The European FP7 UROMOL Project

31 March 2020

1 reference

Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay

31 March 2020

1 reference

Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance

31 March 2020

1 reference

Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer

31 March 2020

1 reference

Genetic modeling of human urinary bladder carcinogenesis

31 March 2020

1 reference

Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract

31 March 2020

1 reference

High throughput comparative genomic hybridization array analysis of multifocal urothelial cancers

31 March 2020

1 reference

Molecular evolution of multiple recurrent cancers of the bladder

31 March 2020

1 reference

Grade progression and regression in recurrent urothelial cancer

31 March 2020

1 reference

Relationship between E-cadherin and fibroblast growth factor receptor 2b expression in bladder carcinomas

31 March 2020

1 reference

Loss of SPARC in bladder cancer enhances carcinogenesis andprogression.

31 March 2020

1 reference

Gene Expression Signatures Predict Outcome in Non-Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study

31 March 2020

1 reference

Re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur Urol 2014;66:609-10

31 March 2020

1 reference

Reply to Mattias Aine, Fredrik Liedberg, Gottfrid Sjödahl, and Mattias Höglund's Letter to the Editor re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New insights into subtypes of invasive bladder cancer: considerations of the clinician. E

31 March 2020

1 reference

Amplification at chromosome 11q13 in transitional cell tumours of the bladder.

31 March 2020

1 reference

12 December 2020

Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma.

1 reference

12 December 2020

Two molecular pathways to transitional cell carcinoma of the bladder.

1 reference

12 December 2020

Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder

1 reference

12 December 2020

Fluorescence in situ hybridization detects frequent chromosome 9 deletions and aneuploidy in histologically normal urothelium of bladder cancer patients

1 reference

12 December 2020

Loss of SPARC in bladder cancer enhances carcinogenesis and progression

1 reference

12 December 2020

Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors

1 reference

12 December 2020

Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract

1 reference

12 December 2020

Elevated expression of pp60c-src in low grade human bladder carcinoma

1 reference

12 December 2020

Histologic-genetic mapping by allele-specific PCR reveals intraurothelial spread of p53 mutant tumor clones.

1 reference

12 December 2020

Partial allelotype of carcinoma in situ of the human bladder

1 reference

12 December 2020

Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters

1 reference

12 December 2020

Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC3817

1 reference

Dimensions Publication ID

1 September 2017

0 references

0 references

1 reference